<code id='550226D6CC'></code><style id='550226D6CC'></style>
    • <acronym id='550226D6CC'></acronym>
      <center id='550226D6CC'><center id='550226D6CC'><tfoot id='550226D6CC'></tfoot></center><abbr id='550226D6CC'><dir id='550226D6CC'><tfoot id='550226D6CC'></tfoot><noframes id='550226D6CC'>

    • <optgroup id='550226D6CC'><strike id='550226D6CC'><sup id='550226D6CC'></sup></strike><code id='550226D6CC'></code></optgroup>
        1. <b id='550226D6CC'><label id='550226D6CC'><select id='550226D6CC'><dt id='550226D6CC'><span id='550226D6CC'></span></dt></select></label></b><u id='550226D6CC'></u>
          <i id='550226D6CC'><strike id='550226D6CC'><tt id='550226D6CC'><pre id='550226D6CC'></pre></tt></strike></i>

          Home / knowledge / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:83

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In